title: [Chemotherapeutic treatment of metastatic ovarian cancer for 8 years. Case report].
abstract: The authors present the history of a 48-year-old woman, who developed pleural effusion, abdominal pain and ascites due to an advanced ovarian cancer. She underwent hysterectomy and bilateral adnexectomy in 2006, and histology revealed FIGO IIIB papillary adenocarcinoma. After surgery the patient recieved the standard, 6 cycle taxol-carboplatin therapy. Taxol-carboplatin therapy was reinitiated because of retroperitoneal lymph node metastases in 2008, but soon the therapy had to be changed because of progression. Thereafter the patient recieved 6 different types of chemo- and biological therapy including the off-label FOLFOX-4 treatment at seventh line. Significant regression in response to FOLFOX-4 therapy was confirmed with a progression free survival of about 9 months. The general condition of the patient was satisfying during the whole chemotherapy, and the side effects were tolerable. The overall survival was 98 months. This case history is a good example for the success of individualized, long term chemotherapy even if ovarian tumor diagnosed at advanced stage as it happened in this case. Orv. Hetil., 2016, 157(44), 1769-1773.
authors: Onkológiai Osztály, Bajcsy-Zsilinszky Kórház és Rendelőintézet Budapest, Maglódi út 89-91., 1106.
authors: Dorottya Katalin
authors: DK
authors: Horváth
authors: Onkológiai Osztály, Bajcsy-Zsilinszky Kórház és Rendelőintézet Budapest, Maglódi út 89-91., 1106.
authors: Judit
authors: J
authors: Kósa
authors: Onkológiai Osztály, Bajcsy-Zsilinszky Kórház és Rendelőintézet Budapest, Maglódi út 89-91., 1106.
authors: Ildikó
authors: I
authors: Futó
authors: Onkológiai Osztály, Bajcsy-Zsilinszky Kórház és Rendelőintézet Budapest, Maglódi út 89-91., 1106.
authors: András
authors: A
authors: Telekes
mesh_terms: D020533:Angiogenesis Inhibitors / Q000008:administration & dosage; D000970:Antineoplastic Agents / Q000008:administration & dosage; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000627:therapeutic use*; D016190:Carboplatin / Q000008:administration & dosage; D004359:Drug Therapy, Combination; D005260:Female; D006801:Humans; D008875:Middle Aged; D009367:Neoplasm Staging; D009378:Neoplasms, Multiple Primary / Q000188:drug therapy*; D010051:Ovarian Neoplasms / Q000188:drug therapy*; D012074:Remission Induction; D016896:Treatment Outcome
chemical_list: D020533:Angiogenesis Inhibitors; D000970:Antineoplastic Agents; D016190:Carboplatin
keywords: FOLFOX-4 therapy; FOLFOX-4-terápia; changed chemotherapy; ovarian cancer; petefészek-daganat; váltott kemoterápia